All In Biotech

Drug Trial Radar · NCT07579936

A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing Regimens

Evaluation of the Safety and Efficacy of SAL056 (Recombinant Human Parathyroid Hormone [1-34] for Injection [56.5 μg]) at Different Doses and Dosing Regimens: A Multicenter, Randomized, Open-Label, Parallel-Controlled Phase II Clinical Trial

Last checked: Nov 19, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Apr 30, 2026

Primary completion

Jul 30, 2026

Study completion Nov 30, 2026

Sponsor

Sponsor type
Industry
Collaborators
Salubris (Suzhou) Pharmaceutical Co., Ltd.
First posted
May 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 45 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, open-label, parallel-controlled Phase II study designed to evaluate the differences in safety among four different dosing regimens of SAL056.

Conditions

  • Postmenopausal Women With Osteoporosis

Interventions

  • SAL056 56.5μgDrug

    SAL056 56.5μg administered once weekly for 8 weeks

  • Intervention Group 1Drug

    Teriparatide Injection daily formulation administered for 2 weeks, followed by SAL056 for 6 weeks.

  • Intervention Group 2Drug

    Teriparatide Injection daily formulation administered for 4 weeks, followed by SAL056 for 4 weeks.

  • Intervention Group 3Drug

    SAL056 28.2μg administered twice weekly for 8 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of treatment-emergent adverse events (TEAEs) and treatment-related adverse events (TRAEs) between each intervention group and the control group during the treatment period,about 10weeksTime frame: during the treatment period,about 10 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.